|
|
|
| The influence of the choice of proper time of brain radiotherapy on the curative effect and survival time of non-small cell lung cancer with brain metastases |
| WANG Zhe YUAN Na ZHU Yanping |
| Radiotherapy Department, the First Affiliated Hospital of Hebei North University, Hebei Province, Zhangjiakou 075000, China |
|
|
|
Abstract Objective To explore the best time of brain radiotherapy in patients of non-small cell lung cancer with brain metastases and its influence on the curative effect and survival time. Methods The clinical data of 106 patients diagnosed as non-small cell lung cancer accompanied by brain metastases in the First Affiliated Hospital of Hebei North University from July 2013 to January 2015 were analyzed retrospectively and they divided into the observation group (n = 54) and the control group (n = 52) according to the clinical symptoms. The observation group was carried out brain radiation after non-small cell lung cancer accompanied by brain metastases, while the control group was given brain radiotherapy after the clinical symptoms of brain metastasis. The initial progress parts of the patients were observed, the curative effect and prognosis were compared between the two groups. Results After the treatment of patients with brain metastases, there was statistically significant difference in the initial progress parts between the two groups (P ＜ 0.05). There were no statistically significant differences in the short term efficacy such as objective response rate and total effective rate (P ＞ 0.05). During the treatment period, the adverse reactions in the two groups were mainly hematological toxicity, gastrointestinal reaction and fatigue. The grade of adverse reactions was mostly in grade Ⅰ/Ⅱ level, Ⅲ/Ⅳ level was less, and there were no statistically significant differences between the two groups in Ⅰ/Ⅱ and Ⅲ/Ⅳ level (P ＞ 0.05). The patients were all followed up and the follow up time was 3-24 months, the median follow-up time was 13.5 months. Before treatment, there was no statistically significant difference in score of life quality between the two groups (P ＞ 0.05), after treatment for 1 year and 2 years, the score of life quality in the observation group were significantly higher than those in the control group, with statistically significant differences (P ＜ 0.05). Conclusion Early whole brain radiotherapy helps to prolong the survival time of patients with non-small cell lung cancer accompanied by brain metastases, delayed brain radiotherapy will have a negative impact on the prognosis of the patients, clinical attention should be focused on.
|
|
|
|
|
|
[1] Ulger S，Demirci NY，Eroglu FN，et al. High FDG uptake predicts poorer survival in locally advanced nonsmall cell lung cancer patients undergoing curative radiotherapy，independently of tumor size [J]. J Cancer Res Clin Oncol，2014， 140（3）：495-502.
[2] 余慧青，王东林，马惠文，等.国产培美曲塞联合顺铂并同步或序贯脑放疗治疗非小细胞肺癌脑转移的疗效[J].中国老年学杂志，2012，32（24）：5433-5436.
[3] 李沫，纪秀杰，周迪，等.厄洛替尼联合全脑放疗治疗非小细胞肺癌脑转移的临床疗效[J].中国老年学杂志，2015， 35（18）：5184-5186.
[4] 苏雷，胡玲，崔桂敏，等.MGMT及IDH1表达与替莫唑胺联合全脑放疗治疗非小细胞肺癌脑转移疗效的关系[J].重庆医学，2017，46（21）：2976-2979.
[5] 周荻，徐欣，谢华英，等.全脑放疗联合靶向治疗与同步放、化疗治疗非小细胞肺癌脑转移疗效分析[J].上海交通大学学报：医学版，2013，33（4）：480-484.
[6] 林珊，韩波，高纯子，等.Iressa与放疗同期治疗非小细胞肺癌脑转移的临床效果及对表皮生长因子的影响[J].中国医药导报，2015，12（32）：21-24.
[7] 刘萍.表皮生长因子受体酪氨酸激酶抑制剂联合放疗治疗非小细胞肺癌脑转移临床观察[J].中华实用诊断与治疗杂志，2013，27（7）：693-694.
[8] 秦虹，张科乾，李文花，等.非小细胞肺癌脑转移全脑放疗联合靶向药物治疗系统评价[J].中华肿瘤防治杂志，2015，22（4）：300-304.
[9] 刘学啸，杜德希，田智峰，等.厄洛替尼联合全脑放疗对非小细胞肺癌脑转移患者的临床疗效及预后影响[J].中国生化药物杂志，2016，36（10）：51-53.
[10] 刘桂梅，张新勇，田翠孟，等.全脑放疗时间对EGFR突变非小细胞肺癌脑转移患者生存的影响[J].中国肺癌杂志，2016，19（8）：501-507.
[11] 钟小玲，黄飚，刘红军，等.非小细胞肺癌脑转移全脑放疗后迟发性脑白质病的MRI研究[J].临床放射学杂志，2015，34（11）：1716-1719.
[12] 辜星婷，赵娅琴，许峰，等.非小细胞肺癌脑转移全脑及病灶局部大分割放射治疗[J].中国肺癌杂志，2016，19（4）：224-229.
[13] 王小磊，刘德泽，王民，等.厄洛替尼联合全脑放疗治疗非小细胞肺癌脑转移的临床观察[J].国际肿瘤学杂志，2015，42（11）：809-812.
[14] 夏云，王志.埃克替尼联合放疗治疗非小细胞肺癌脑转移的疗效及安全性探讨[J].中国现代医生，2017，55（36）：78-80.
[15] 王洋，方健，聂鋆，等.非小细胞肺癌脑转移放疗时机的选择及疗效预后分析[J].中国肺癌杂志，2016，19（8）：508-514.
[16] 王柱.非小细胞肺癌脑转移放疗时机的选择及对疗效和预后分析的影响[J].世界临床医学，2017，11（15）：32. |
|
|
|
